Switch theme
Sign up to access all valuation multiples
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
2018
32
Last FY Revenue n/a
Last FY EBITDA -$1.9M
$3.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Jyong Biotech achieved revenue of n/a and an EBITDA of -$1.9M.
Jyong Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jyong Biotech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$1.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$2.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$3.0M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | $17.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Jyong Biotech's stock price is $45.
Jyong Biotech has current market cap of $3.4B, and EV of $3.4B.
See Jyong Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4B | $3.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Jyong Biotech has market cap of $3.4B and EV of $3.4B.
Jyong Biotech's trades at n/a EV/Revenue multiple, and -1834.5x EV/EBITDA.
Equity research analysts estimate Jyong Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jyong Biotech's P/E ratio is not available.
See valuation multiples for Jyong Biotech and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1834.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1663.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1126.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -943.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJyong Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.
Jyong Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jyong Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jyong Biotech and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| ABVC BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jyong Biotech acquired XXX companies to date.
Last acquisition by Jyong Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Jyong Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Jyong Biotech founded? | Jyong Biotech was founded in 2018. |
| Where is Jyong Biotech headquartered? | Jyong Biotech is headquartered in United States of America. |
| How many employees does Jyong Biotech have? | As of today, Jyong Biotech has 32 employees. |
| Who is the CEO of Jyong Biotech? | Jyong Biotech's CEO is Ms. Fu-Feng Kuo. |
| Is Jyong Biotech publicy listed? | Yes, Jyong Biotech is a public company listed on NAS. |
| What is the stock symbol of Jyong Biotech? | Jyong Biotech trades under MENS ticker. |
| When did Jyong Biotech go public? | Jyong Biotech went public in 2025. |
| Who are competitors of Jyong Biotech? | Similar companies to Jyong Biotech include e.g. ABVC BioPharma, |
| What is the current market cap of Jyong Biotech? | Jyong Biotech's current market cap is $3.4B |
| Is Jyong Biotech profitable? | Yes, Jyong Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
